Ifosfamide related encephalopathy: the need for a timely EEG evaluation

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Ifosfamide is a widely used alkylating agent for various cancers.
• High-dose ifosfamide is associated with a 10-40% incidence of encephalopathy.
• Early detection of ifosfamide-related encephalopathy is crucial for patient management.

Purpose of the Study:

• To emphasize the utility of electroencephalogram (EEG) in identifying ifosfamide-induced encephalopathy.
• To explore the role of EEG in managing patients experiencing ifosfamide-related neurological toxicity.

Main Methods:

• Retrospective analysis of clinical data and EEG recordings from five patients.
• Patients were admitted to MD Anderson Cancer Center between 2009-2012.
• Focus on patients who developed acute encephalopathy following ifosfamide administration.

Main Results:

• Encephalopathy symptoms manifested within 12 hours to 2 days after ifosfamide administration.
• EEG findings included epileptiform discharges, triphasic waves, and diffuse slowing.
• Repeat EEGs within 24 hours showed improvement correlating with clinical recovery.

Conclusions:

• EEG changes severity directly correlates with ifosfamide-related encephalopathy severity.
• Prompt EEG evaluation is recommended for ifosfamide-treated patients exhibiting encephalopathy symptoms.
• Timely EEG monitoring can guide management and predict patient recovery.